Immunome CMO exercises options, sells 55K shares
Immunome Inc. Chief Medical Officer Robert Lechleider exercised options and sold shares of common stock.
Rhea-AI Filing Summary
Immunome Inc. Chief Medical Officer Robert Lechleider exercised options and sold shares of common stock. He exercised 55,000 shares at $8.73 per share through an employee stock option, then sold 55,000 shares in open-market transactions at weighted average prices of $19.56 and $20.66.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 26, 2026. After these transactions, he directly holds 15,805 shares of common stock and 345,000 employee stock options, which vest over time and expire on October 26, 2033.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 55,000 shares ($612K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Lechleider Robert
Role
Chief Medical Officer
Sold
55,000 shs ($1.09M)
Approx. gross sale proceeds
$1.09M
Approx. exercise cost
$480K
Approx. pre-tax spread
$612K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 55,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 55,000 | $8.73 | $480K |
| Sale | Common Stock | 40,580 | $19.56 | $794K |
| Sale | Common Stock | 14,420 | $20.66 | $298K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 345,000 contracts (Direct);
Common Stock — 15,805 shares (Direct)
Footnotes (4)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
- F2. The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3. The weighted average sale price for the transaction report was $20.66, and the range of prices were between $20.275 and $21.02, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4. 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
Key Figures
Shares sold: 55,000 shares
Sale price tranche 1: $19.56 per share
Sale price tranche 2: $20.66 per share
+5 more
8 metrics
Shares sold
55,000 shares
Open-market sales on June 25, 2026
Sale price tranche 1
$19.56 per share
Weighted average price for 40,580 shares
Sale price tranche 2
$20.66 per share
Weighted average price for 14,420 shares
Options exercised
55,000 options
Employee stock option exercise on June 25, 2026
Option exercise price
$8.73 per share
Conversion or exercise price of employee stock option
Shares held after
15,805 shares
Direct common stock holdings after transactions
Options held after
345,000 options
Remaining employee stock options after exercise
Option expiration
October 26, 2033
Expiration date of the option grant
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Employee Stock Option (right to buy), exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan financial
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255..."
Employee Stock Option (right to buy) financial
"Employee Stock Option (right to buy) listed as a derivative security with underlying common stock shares..."
exercise or conversion of derivative security financial
"Transaction code M is described as Exercise or conversion of derivative security in connection with the option exercise..."
vesting financial
"25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Immunome (IMNM) Chief Medical Officer Robert Lechleider do in this Form 4?
He exercised 55,000 stock options and sold 55,000 common shares. The sales occurred in open-market transactions, converting part of his option position into cash while retaining both shares and additional unexercised options.
Were the Immunome (IMNM) insider sales made under a Rule 10b5-1 plan?
Yes, the sales were executed pursuant to a Rule 10b5-1 trading plan. The plan was adopted by Robert Lechleider on March 26, 2026, indicating the trades were pre-scheduled rather than timed on an ad hoc discretionary basis.
What were the terms of the exercised Immunome (IMNM) stock options?
He exercised 55,000 employee stock options with a conversion or exercise price of $8.73 per share. These options relate to underlying Immunome common stock and are part of a larger grant that continues to vest over several years.
How does the vesting schedule work for the Immunome (IMNM) options mentioned?
For this option grant, 25% of the shares vested on October 16, 2024. The remaining shares vest in equal installments each month over the following three years, gradually increasing his exercisable option position over time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
